Last reviewed · How we verify
NCT07501884: REDUCER
REDUCER Trial (TXA in Urethroplasty)
Phase 4 trial testing Tranexamic Acid in Urethral Stricture in 40 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Amjad Alwaal, MD, MSc, FRCSC, FACS |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tranexamic Acid (Tranexamic Acid) — full drug profile →
- Urethroplasty
Conditions studied
- Urethral Stricture — all drugs for Urethral Stricture →
- Urethral Diseases — all drugs for Urethral Diseases →
Sponsor
Amjad Alwaal, MD, MSc, FRCSC, FACS
Who can join
18 and older, male only, with Urethral Stricture or Urethral Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07501884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tranexamic Acid
Trials testing the same drug.
- NCT07460518 — Tranexamic Acid for Bleeding Reduction During TURP Surgery · Phase 4 · not yet recruiting
- NCT07390799 — Prophylactic Tranexamic Acid in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07078942 — Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section · Phase 4 · not yet recruiting
- NCT07263841 — Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigme · Phase 2 · active not recruiting
- NCT06983886 — The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Urethral Stricture
Currently open trials in the same condition.
- NCT07403786 — Urethral Resistive Index (URI): A New Parameter for Diagnosing Urethral Obstruction · recruiting
- NCT07074717 — Penile Skin Versus Buccal Mucosal Graft in Augmentation Urethroplasty for Long Anterior Urethral Stricture · NA · recruiting
- NCT06362083 — Urethral Stricture Database · recruiting
- NCT05383274 — Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters · Phase 4 · recruiting
- NCT04965025 — Multi-stage Urethroplasty with Augmentation Using a Dorsal Graft Inlay Technique Comparing Graft Use in First or Second · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07501884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amjad Alwaal, MD, MSc, FRCSC, FACS
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07501884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing